{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 413, "pageCount": 415, "prevPage": 412, "nextPage": 414, "slideType": "testimonial", "function": "diagnose_problem", "density": "dense", "nDataPoints": 0, "notes": "The slide uses a Q&A format to present primary research findings from a consultation call.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/413", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-413", "components": [ { "bbox": null, "kind": "callout", "text": "The nephrologist indicated no discussion or buzz about Vykat among endocrinologists who treat PWS patients, among other hurdles for the drug – it’s “pretty quiet.”", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64cf-7128-a313-77cab9f428dc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.86, "x": 0.07, "y": 0.73 }, "kind": "paragraph", "text": "Not visited by a drug rep; only prescribing if a patient pushes for it; unlikely to spend time chasing insurance approval Q: “How much enthusiasm have you heard around this drug? Is it pretty quiet? Is it a game changer? What’s the reaction out there?” A: “From the folks that I’ve seen with the disease, obviously, they’re on top of it. I have not been visited by a drug rep or anyone like that. I do think that it’s feast or famine. If we do have a patient, they want to get on it, I’m happy to help them, as long as it doesn’t become labor-intensive. But sometimes, the pre-authorization process is labor-intensive, and you have to write a few letters and stuff. It takes a lot of time.” Q: “And then how much do you think the $500,000, $1 million a year price will impact how many patients physicians put on it?” A: “I think it’s going to be tough to justify it if you have a lot of volume. But I think the physicians will try it once or twice. And if they find out that they’re not getting approved or there’s too much work, they may try the generic.”– Nephrologist who manages PWS patients,", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "88b5e6e7-829a-493f-baee-c98f0a8de02f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.86, "x": 0.07, "y": 0.58 }, "kind": "paragraph", "text": "No chatter about Vykat from PWS physicians; “pretty quiet” Q: “What have you heard from colleagues in the Chicago area? Are you hearing a lot of chatter about Vykat or not so much?” A: “No.” Q: “People that you know in your professional circle that treat PWS patients, is anybody emailing, texting each other? Or pretty quiet?” A: “Pretty quiet.” –Nephrologist who manages PWS patients,", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c2836655-51bd-4947-8af6-e92132a0862d", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“Pretty quiet.” — Nephrologist who manages PWS patients; “I have not been visited by a drug rep or anyone like that. I do think that it's feast or famine. If we do have a patient, they want to get on it, I'm happy to help them, as long as it doesn't become labor-intensive. But sometimes, the pre-authorization process is labor-intensive, and you have to write a few letters and stuff. It takes a lot of time.” — Nephrologist who manages PWS patients; “I think it's going to be tough to justify it if you have a lot of volume. But I think the physicians will try it once or twice. And if they find out that they're not getting approved or there's too much work, they may try the generic.” — Nephrologist who manages PWS patients.", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64cf-7128-a313-7ad9aa5becee", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7e081b38-281c-40bf-9bcb-cba061ae18f6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.45, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "The nephrologist indicated no discussion or buzz about Vykat among endocrinologists who treat PWS patients, among other hurdles for the drug – it’s “pretty quiet.”", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3d09fae2-1b38-4564-a5cf-4201ccab543c", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }